دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Deep brain stimulation targets in epilepsy: Systematic review and meta-analysis of anterior and centromedian thalamic nuclei and hippocampus
Artur Vetkas, Anton Fomenko, Jürgen Germann, Can Sarica, Christian Iorio-Morin, Nardin Samuel, Kazuaki Yamamoto, Vanessa Milano, Cletus Cheyuo, Ajmal Zemmar, Gavin Elias, Alexandre Boutet, Aaron Loh, Brendan Santyr, Dave Gwun, Jordy Tasserie, Suneil K. Kalia, Andres M. Lozano
doi : 10.1111/epi.17157
Pages: 513-524 First Published: 03 January 2022
Deep brain stimulation (DBS) is a neuromodulatory treatment used in patients with drug-resistant epilepsy (DRE). The primary goal of this systematic review and meta-analysis is to describe recent advancements in the field of DBS for epilepsy, to compare the results of published trials, and to clarify the clinical utility of DBS in DRE. A systematic literature search was performed by two independent authors. Forty-four articles were included in the meta-analysis (23 for anterior thalamic nucleus [ANT], 8 for centromedian thalamic nucleus [CMT], and 13 for hippocampus) with a total of 527 patients. The mean seizure reduction after stimulation of the ANT, CMT, and hippocampus in our meta-analysis was 60.8%, 73.4%, and 67.8%, respectively. DBS is an effective and safe therapy in patients with DRE. Based on the results of randomized controlled trials and larger clinical series, the best evidence exists for DBS of the anterior thalamic nucleus. Further randomized trials are required to clarify the role of CMT and hippocampal stimulation. Our analysis suggests more efficient deep brain stimulation of ANT for focal seizures, wider use of CMT for generalized seizures, and hippocampal DBS for temporal lobe seizures. Factors associated with clinical outcome after DBS for epilepsy are electrode location, stimulation parameters, type of epilepsy, and longer time of stimulation. Recent advancements in anatomical targeting, functional neuroimaging, responsive neurostimulation, and sensing of local field potentials could potentially lead to improved outcomes after DBS for epilepsy and reduced sudden, unexpected death of patients with epilepsy. Biomarkers are needed for successful patient selection, targeting of electrodes and optimization of stimulation parameters.
The use of rodent models to better characterize the relationship among epilepsy, sleep, and memory
John E. Merten, Sadie A. Villarrubia, Kevin S. Holly, Aaron S. Kemp, Allison C. Kumler, Linda J. Larson-Prior, Teresa A. Murray
doi : 10.1111/epi.17161
Pages: 525-536 First Published: 05 January 2022
Epilepsy, a neurological disorder characterized by recurrent seizures, is known to be associated with impaired sleep and memory. Although the specific mechanisms underlying these impairments are uncertain, the known role of sleep in memory consolidation suggests a potential relationship may exist between seizure activity, disrupted sleep, and memory impairment. A possible mediator in this relationship is the sleep spindle, the characteristic electroencephalographic (EEG) feature of non-rapid-eye-movement (NREM) sleep in humans and other mammals. Growing evidence supports the idea that sleep spindles, having thalamic origin, may mediate the process of long-term memory storage and plasticity by generating neuronal conditions that favor these processes. To study this potential relationship, a single model in which memory, sleep, and epilepsy can be simultaneously observed is of necessity. Rodent models of epilepsy appear to fulfill this requirement. Not only do rodents express both sleep spindles and seizure-induced sleep disruptions, but they also allow researchers to invasively study neurobiological processes both pre- and post- epileptic onset via the artificial induction of epilepsy (a practice that cannot be carried out in human subjects). However, the degree to which sleep architecture differs between rodents and humans makes direct comparisons between the two challenging. This review addresses these challenges and concludes that rodent sleep studies are useful in observing the functional roles of sleep and how they are affected by epilepsy.
Epilepsy and brain network hubs
Jessica Royer, Boris C. Bernhardt, Sara Larivière, Ezequiel Gleichgerrcht, Bernd J. Vorderwülbecke, Serge Vulliémoz, Leonardo Bonilha
doi : 10.1111/epi.17171
Pages: 537-550 First Published: 28 January 2022
Epilepsy is a disorder of brain networks. A better understanding of structural and dynamic network properties may improve epilepsy diagnosis, treatment, and prognostics. Hubs are brain regions with high connectivity to other parts of the brain and are typically situated along the brain's most efficient communication pathways, supporting large-scale brain wiring and many higher order neural functions. The visualization and analysis of hubs offers a perspective on regional and global network organization and can provide novel insights into brain disorders and epilepsy. By notably supporting the interaction between various brain networks, hubs may be implicated in seizure spread and in epilepsy-related phenotypes. In this review, we will discuss the growing literature on atypical hub organization in common epilepsy syndromes, both related to neuroimaging of brain structure and function, and related to neurophysiological data from magneto- and electroencephalographic measures of neural dynamics. With studies increasingly exploring the clinical utility of network neuroscience approaches, we highlight the potential of hub mapping as a candidate biomarker of cognitive dysfunction and postsurgical seizure outcome. We will conclude the review with a discussion of current limitations and outlook for future research.
The worldwide epilepsy treatment gap: A systematic review and recommendations for revised definitions – A report from the ILAE Epidemiology Commission
Churl-Su Kwon, Ryan G. Wagner, Arturo Carpio, Nathalie Jetté, Charles R. Newton, David J. Thurman
doi : 10.1111/epi.17112
Pages: 551-564 First Published: 10 January 2022
In order to more appropriately apply and understand the “epilepsy treatment gap� (ETG) concept in current health systems, revised conceptual and operational definitions of ETG are timely and necessary. This article therefore systematically reviews worldwide studies of the ETG, distinguishing high-, middle-, and low-income regions, and provides recommendations for an updated International League Against Epilepsy (ILAE) definition of ETG.
Proposal for an updated seizure classification framework in clinical trials
Claude Steriade, Michael R. Sperling, Bree DiVentura, Meryl Lozano, Renée A. Shellhaas, Sudha Kilaru Kessler, Dennis Dlugos, Jacqueline French
doi : 10.1111/epi.17120
Pages: 565-572 First Published: 07 January 2022
The International League Against Epilepsy (ILAE) seizure classification scheme has been periodically updated to improve its reliability and applicability to clinicians and researchers alike. Here, members of the Epilepsy Study Consortium propose a pragmatic seizure classification, based on the ILAE scheme, designed for use in clinical trials with a focus on outcome measures that have high reliability, broad interpretability across stakeholders, and clinical relevance in the context of the development of novel antiseizure medications. Controversies around the current ILAE classification scheme are discussed in the context of clinical trials, and pragmatic simplifications to the existing scheme are proposed, for intended use by investigators, industry sponsors, and regulatory agencies.
Systematic review of frequency of felt and enacted stigma in epilepsy and determining factors and attitudes toward persons living with epilepsy—Report from the International League Against Epilepsy Task Force on Stigma in Epilepsy
Churl-Su Kwon, Ann Jacoby, Amza Ali, Joan Austin, Gretchen L. Birbeck, Patricia Braga, J. Helen Cross, Hanneke de Boer, Tarun Dua, Paula T. Fernandes, Kirsten M. Fiest, Jonathan Goldstein, Sheryl Haut, Diane Lorenzetti, Janet Mifsud, Solomon Moshe, Karen L. Parko, Manjari Tripathi, Samuel Wiebe, Nathalie Jette
doi : 10.1111/epi.17135
Pages: 573-597 First Published: 05 January 2022
To review the evidence of felt and enacted stigma and attitudes toward persons living with epilepsy, and their determining factors.
Epilepsy-related stigma and attitudes: Systematic review of screening instruments and interventions - Report by the International League Against Epilepsy Task Force on Stigma in Epilepsy
Joan K. Austin, Gretchen Birbeck, Karen Parko, Churl-Su Kwon, Paula T. Fernandes, Patricia Braga, Kirsten M. Fiest, Amza Ali, J. Helen Cross, Hanneke de Boer, Tarun Dua, Sheryl R. Haut, Ann Jacoby, Diane L. Lorenzetti, Janet Mifsud, Solomon L. Moshé, Manjari Tripathi, Samuel Wiebe, Nathalie Jette
doi : 10.1111/epi.17133
Pages: 598-628 First Published: 05 January 2022
Common functional connectivity alterations in focal epilepsies identified by machine learning
Taha Gholipour MD, Xiaozhen You PhD, Steven M. Stufflebeam MD, PhD, Murray Loew PhD, Mohamad Z. Koubeissi MD, Victoria L. Morgan PhD, William D. Gaillard MD
doi : 10.1111/epi.17160
Pages: 629-640 First Published: 04 January 2022
This study was undertaken to identify shared functional network characteristics among focal epilepsies of different etiologies, to distinguish epilepsy patients from controls, and to lateralize seizure focus using functional connectivity (FC) measures derived from resting state functional magnetic resonance imaging (MRI).
Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model
Hoi Yau Chan, Ben F. M. Wijnen, Marian H. J. M. Majoie, Silvia M. A. A. Evers, Mickaël Hiligsmann
doi : 10.1111/epi.17158
Pages: 641-651 First Published: 30 December 2021
This study was undertaken to estimate the cost-effectiveness of deep brain stimulation (DBS) compared with vagus nerve stimulation (VNS) and care as usual (CAU) for adult patients with refractory epilepsy from a health care perspective using a lifetime decision analytic model.
Intracranial electroencephalographic biomarker predicts effective responsive neurostimulation for epilepsy prior to treatment
Brittany H. Scheid, John M. Bernabei, Ankit N. Khambhati, Sofia Mouchtaris, Jay Jeschke, Dani S. Bassett, Danielle Becker, Kathryn A. Davis, Timothy Lucas, Werner Doyle, Edward F. Chang, Daniel Friedman, Vikram R. Rao, Brian Litt
doi : 10.1111/epi.17163
Pages: 652-662 First Published: 07 January 2022
Despite the overall success of responsive neurostimulation (RNS) therapy for drug-resistant focal epilepsy, clinical outcomes in individuals vary significantly and are hard to predict. Biomarkers that indicate the clinical efficacy of RNS—ideally before device implantation—are critically needed, but challenges include the intrinsic heterogeneity of the RNS patient population and variability in clinical management across epilepsy centers. The aim of this study is to use a multicenter dataset to evaluate a candidate biomarker from intracranial electroencephalographic (iEEG) recordings that predicts clinical outcome with subsequent RNS therapy.
Adults with tuberous sclerosis complex: A distinct patient population
Kenan Bachour, Andrew A. House, Danielle M. Andrade, Mary Connolly, Dereck B. Debicki, Richard Desbiens, Tadeu A. Fantaneanu, Paulina Kyriakopoulos, Jean-Baptiste Lattouf, Ana Suller-Marti, Paula T. Marques, Mark R. Keezer
doi : 10.1111/epi.17159
Pages: 663-671 First Published: 29 December 2021
There are few data on adults living with tuberous sclerosis complex (TSC), with most studies focusing on pediatric populations. The objective of our study was to examine a large national cohort of adults with TSC, and to describe the clinical characteristics of these adults and the nature of the multidisciplinary care that they receive.
Pediatric Epilepsy Learning Healthcare System Quality of Life (PELHS-QOL-2): A novel health-related quality of life prompt for children with epilepsy
Pooja D. Shah, Michelle Yun, Alan Wu, Rachel A. Arnesen, Margaret Storey, Max Sokoloff, Renée A. Shellhaas, Cassie Turnage, Erika J. Axeen, Howard P. Goodkin, Anup D. Patel, Evelynne Wentzel, Avani C. Modi, Zachary M. Grinspan
doi : 10.1111/epi.17156
Pages: 672-685 First Published: 31 December 2021
Pediatric epilepsy is often associated with diminished health-related quality of life (HRQOL). Our aim was to establish the validity of the Pediatric Epilepsy Learning Healthcare System Quality of Life (PELHS-QOL-2) questions, a novel two-item HRQOL prompt for children with epilepsy, primarily for use in clinical care.
Therapeutic drug monitoring of fenfluramine in clinical practice: Pharmacokinetic variability and impact of concomitant antiseizure medications
An-Sofie Schoonjans, Laurence Roosens, Wendy Dewals, Bernard P. Paelinck, Berten Ceulemans
doi : 10.1111/epi.17162
Pages: 686-696 First Published: 15 January 2022
This study was undertaken to determine the plasma concentration and pharmacokinetic variability of fenfluramine (FFA) and its main active metabolite norfenfluramine (norFFA) in relation to the prevalence of adverse effects in patients with refractory epilepsy treated with FFA. In addition, the interaction with concomitant antiseizure medications including stiripentol (STP) is studied.
The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers
Kristopher M. Kahlig, Liam Scott, Robert J. Hatch, Andrew Griffin, Gabriel Martinez Botella, Zoë A. Hughes, Marion Wittmann
doi : 10.1111/epi.17149
Pages: 697-708 First Published: 17 January 2022
This study investigates the effects of PRAX-562 on sodium current (INa), intrinsic neuronal excitability, and protection from evoked seizures to determine whether a preferential persistent INa inhibitor would exhibit improved preclinical efficacy and tolerability compared to two standard voltage-gated sodium channel (NaV) blockers.
CASPR2-IgG-associated autoimmune seizures
Emilio R. Garrido Sanabria, Anza Zahid, Jeffrey Britton, Gregory J. Kraus, Alfonso Sebastian López-Chiriboga, Anastasia Zekeridou, Eoin P. Flanagan, Andrew McKeon, John R. Mills, Sean J. Pittock, Divyanshu Dubey
doi : 10.1111/epi.17164
Pages: 709-722 First Published: 15 January 2022
This study was undertaken to report clinical presentations and outcomes of CASPR2-IgG-associated seizures.
Association of ultra-rare coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study
Mahmoud Koko, Joshua E. Motelow, Kate E. Stanley, Dheeraj R. Bobbili, Ryan S. Dhindsa, Patrick May, Canadian Epilepsy Network, Epi4K Consortium, Epilepsy Phenome/Genome Project, EpiPGX Consortium, EuroEPINOMICS-CoGIE Consortium
doi : 10.1111/epi.17166
Pages: 723-735 First Published: 15 January 2022
We aimed to identify genes associated with genetic generalized epilepsy (GGE) by combining large cohorts enriched with individuals with a positive family history. Secondarily, we set out to compare the association of genes independently with familial and sporadic GGE.
Epilepsia – March 2022 – Announcements
doi : 10.1111/epi.17196
Pages: 736-738 First Published: 28 February 2022
